Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - methadone hydrochloride 10 mg/ml - oral solution - 10 mg/ml - active: methadone hydrochloride 10 mg/ml excipient: brilliant blue fcf cherry flavour it1037 citric acid monohydrate glycerol hyetellose purified water sodium benzoate xylitol - indicated in detoxification and maintenance treatment as a substitute for heroin or other morphine-like drugs to suppress the opiate-agonist abstinence syndrome in patients who are dependent on these drugs.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - methadone hydrochloride 1 mg/ml - oral solution - 1 mg/ml - active: methadone hydrochloride 1 mg/ml excipient: brilliant blue fcf cherry flavour it1037 citric acid monohydrate glycerol hyetellose purified water sodium benzoate tartrazine xylitol - indicated in detoxification and maintenance treatment as a substitute for heroin or other morphine-like drugs to suppress the opiate-agonist abstinence syndrome in patients who are dependent on these drugs.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - methadone hydrochloride 5 mg/ml - oral solution - 5 mg/ml - active: methadone hydrochloride 5 mg/ml excipient: caramel cherry flavour it1037 citric acid monohydrate glycerol hyetellose purified water sodium benzoate xylitol - indicated in detoxification and maintenance treatment as a substitute for heroin or other morphine-like drugs to suppress the opiate-agonist abstinence syndrome in patients who are dependent on these drugs.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - oxcarbazepine 60 mg/ml;  ;   - oral suspension - 60 mg/ml - active: oxcarbazepine 60 mg/ml     excipient: ascorbic acid citrus limon dispersible cellulose macrogol stearate 400 methyl hydroxybenzoate propyl hydroxybenzoate propylene glycol purified water saccharin sodium sorbic acid sorbitol - trileptal is indicated in adults and children aged 1 month and above for the treatment of · partial seizures (which include the seizure subtypes of simple, complex and partial seizures evolving to secondarily generalised seizures) and · generalised tonic-clonic seizures. trileptal is indicated as a first-line antiepileptic drug for use as monotherapy or adjunctive therapy. trileptal can replace other antiepileptic drugs when current therapy provides insufficient seizure control.

Israel - anglès - Ministry of Health

teva pharmaceutical industries ltd, israel - methadone hydrochloride - solution - methadone hydrochloride 0.4 mg/ml - methadone - methadone - relief of moderate to severe pain.

Unió Europea - anglès - EMA (European Medicines Agency)

recordati rare diseases - zinc - hepatolenticular degeneration - other alimentary tract and metabolism products, - treatment of wilson's disease.

Estats Units - anglès - NLM (National Library of Medicine)

stat rx usa llc - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c), naltrexone hydrochloride (unii: z6375yw9sf) (naltrexone - unii:5s6w795cqm) - morphine sulfate 20 mg - embeda is an extended-release oral formulation of morphine sulfate and naltrexone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. embeda is not intended for use as a prn analgesic. embeda is not indicated for acute/postoperative pain or if the pain is mild or not expected to persist for an extended period of time. embeda is only indicated for postoperative use if the patient is already receiving chronic opioid therapy prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate embeda is contraindicated in patients with a known hypersensitivity to morphine, morphine salts, naltrexone, or in any situation where opioids are contraindicated. embeda is contraindicated in patients with significant respiratory depression in u

Estats Units - anglès - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - promethazine hydrochloride (unii: r61zeh7i1i) (promethazine - unii:ff28ejq494), codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j) - promethazine hydrochloride 6.25 mg in 5 ml - promethazine with codeine oral solution is indicated for the temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold. the combination of promethazine hydrochloride and codeine phosphate is contraindicated in pediatric patients less than 6 years of age, because the combination may cause fatal respiratory depression in this age population. codeine sulfate is contraindicated for post-operative pain management in children who have undergone tonsillectomy and/or adenoidectomy. (see warnings - death related to ultra- rapid metabolism of codeine to morphine ). codeine is contraindicated in patients with a known hypersensitivity to the drug. promethazine hydrochloride is contraindicated in comatose states, and in individuals known to be hypersensitive or to have had an idiosyncratic reaction to promethazine or to other phenothiazines. antihistamines and codeine are both contraindicated for use in the treatment of lower respiratory tract symptoms, including asthma. prometha

Estats Units - anglès - NLM (National Library of Medicine)

unit dose services - promethazine hydrochloride (unii: r61zeh7i1i) (promethazine - unii:ff28ejq494), codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j) - promethazine hydrochloride 6.25 mg in 5 ml - promethazine with codeine oral solution is indicated for the temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold. promethazine with codeine oral solution is contraindicated in pediatric patients less than 12 years of age. (see warnings - ultra- rapid metabolism of codeine and respiratory depression ). promethazine with codeine oral solution is contraindicated for post-operative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy. (see warnings - ultra- rapid metabolism of codeine and respiratory depression ). codeine is contraindicated in patients with a known hypersensitivity to the drug. promethazine hydrochloride is contraindicated in comatose states, and in individuals known to be hypersensitive or to have had an idiosyncratic reaction to promethazine or to other phenothiazines. antihistamines and codeine are both contraindicated for use in the treatment of lower respiratory tract symptoms, including asthma. prom

Estats Units - anglès - NLM (National Library of Medicine)

tris pharma inc - hydrocodone bitartrate (unii: no70w886kk) (hydrocodone - unii:6yks4y3wq7), chlorpheniramine maleate (unii: v1q0o9oj9z) (chlorpheniramine - unii:3u6io1965u) - hydrocodone bitartrate 10 mg in 5 ml - hydrocodone polistirex and chlorpheniramine polistirex extended-release suspension is indicated for the temporary relief of cough and upper respiratory symptoms associated with allergy or the common cold in patients 18 years of age and older. important limitations of use : • not indicated for pediatric patients under 18 years of age [see use in specific populations (8.4 ) ]. • contraindicated in pediatric patients less than 6 years of age [see contraindications (4) ]. • because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.1) ], reserve hydrocodone polistirex and chlorpheniramine polistirex for use in adult patients for whomthe benefits of cough suppression are expected to outweigh the risks, and in whom an adequateassessment of the etiology of the cough has been made. hydrocodone polistirex and chlorpheniramine polistirex is contraindicated for: - all children younger than 6 years of age [see warnings and precautions (5.2 , 5.3 ),